Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,536 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Among authors: ikeda m. Int J Clin Oncol. 2023 Oct;28(10):1237-1258. doi: 10.1007/s10147-023-02397-9. Epub 2023 Aug 20. Int J Clin Oncol. 2023. PMID: 37599324 Free PMC article.
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: ikeda m. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Yamada I, Morizane C, Okusaka T, Mizusawa J, Kataoka T, Ueno M, Ikeda M, Okano N, Todaka A, Shimizu S, Mizuno N, Sekimoto M, Tobimatsu K, Yamaguchi H, Nishina T, Shirakawa H, Kojima Y, Oono T, Kawamoto Y, Furukawa M, Iwai T, Sudo K, Okamura K, Yamashita T, Kato N, Shioji K, Shimizu K, Nakagohri T, Kamata K, Ishii H, Furuse J; JCOG-HBPOG. Yamada I, et al. Among authors: ikeda m. Sci Rep. 2022 Jan 19;12(1):987. doi: 10.1038/s41598-021-04550-8. Sci Rep. 2022. PMID: 35046457 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Among authors: ikeda m. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Kudo M, et al. Among authors: ikeda m. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. Gut. 2020. PMID: 31801872 Free PMC article. Clinical Trial.
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Current status of the cost burden of first-line systemic treatment for patients with advanced hepatocellular carcinoma in Japan, 2021-22.
Imaoka H, Sasaki K, Machida R, Nagano H, Satoi S, Ikeda M, Kobayashi S, Yamashita T, Okusaka T, Ido A, Hatano E, Miwa H, Ueno M, Nakao K, Shimizu S, Kuramochi H, Sakamori R, Tsumura H, Okano N, Shioji K, Shirakawa H, Akutsu N, Tsuji K, Ishii H, Umemoto K, Asagi A, Ueno M; JCOG Hepatobiliary and Pancreatic Oncology Group. Imaoka H, et al. Among authors: ikeda m. Jpn J Clin Oncol. 2024 Jun 7:hyae048. doi: 10.1093/jjco/hyae048. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 38843879
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, Moriguchi M, Watanabe S, Ikeda M, Kuroda H, Kawaoka T, Hiraoka A, Yasui Y, Kuzuya T, Sato R, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Nakamoto S, Ozawa Y, Tsuchiya K, Atsukawa M, Aikata H, Aramaki T, Oka S, Morimoto N, Kurosaki M, Itoh Y, Izumi N, Kato N. Kobayashi K, et al. Among authors: ikeda m. Invest New Drugs. 2024 Jun 6. doi: 10.1007/s10637-024-01441-3. Online ahead of print. Invest New Drugs. 2024. PMID: 38842657
Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.
Inui N, Suzuki T, Tanaka K, Karayama M, Inoue Y, Mori K, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Matsuura S, Nishimoto K, Matsui T, Asada K, Hashimoto D, Fujii M, Niwa M, Uehara M, Matsuda H, Koda K, Ikeda M, Inami N, Tamiya Y, Kato M, Nakano H, Mino Y, Enomoto N, Suda T. Inui N, et al. Among authors: ikeda m. J Clin Oncol. 2024 Jun 4:JCO2400278. doi: 10.1200/JCO.24.00278. Online ahead of print. J Clin Oncol. 2024. PMID: 38833659
Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
Ogata Y, Sadahiro S, Sakamoto K, Tsuchiya T, Takahashi T, Ohge H, Sato T, Kondo K, Baba H, Itabashi M, Ikeda M, Hamada M, Maeda K, Masuko H, Takahashi K, Kusano M, Hyodo I, Sakamoto J, Taguri M, Morita S. Ogata Y, et al. Among authors: ikeda m. Int J Clin Oncol. 2024 Jun 4. doi: 10.1007/s10147-024-02565-5. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38833114
6,536 results